Derivation of clinical grade human embryonic stem cell lines for therapeutic applications

Embryonic stem cells must be produced to pharmaceutical-grade standards before they can be tested as treatments for patients. Currently, these cells can only be used in laboratory research, not in human therapies. This project aims to change that by creating human embryonic stem cell lines that are free of infectious agents, free of animal contaminants, and genetically stable—meeting a set of manufacturing rules known as Good Manufacturing Practice (GMP). Without such cell lines, potential stem-cell therapies for heart disease, type 1 diabetes, Parkinson’s disease, and motor neurone disease cannot move from the lab into clinical trials. If successful, the project will deposit the resulting cell lines in the UK Stem Cell Bank, making them freely available to the medical community. That would give researchers across the country a standardised, safe starting material for developing and testing new treatments. This is a necessary piece of infrastructure for regenerative medicine—the kind of behind-the-scenes work that must happen before any therapy can reach a patient.